ARMO BioSciences Expands Leadership Team with the Appointment of Gail L. Brown, M.D. as Chief Medical Officer

REDWOOD CITY, Calif., April 18, 2016 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced the appointment of Gail L. Brown, M.D. to the position of Chief Medical Officer.  Dr. Brown will be responsible for the clinical development of the company's pipeline of immunotherapies including the lead product candidate AM0010, several cytokines with therapeutic potential, and an anti-PD-1 monoclonal antibody for the treatment of advanced solid tumors.

"In this significant year of new clinical data, Gail's extensive experience adds breadth and depth to our executive team as we prepare for the initiation of registration-enabling phase 2-3 studies with AM0010," said Peter Van Vlasselaer, Ph.D., Chief Executive Officer of ARMO.  "Gail has navigated a number of drug candidates from phase 1 to pivotal phase 3 studies, both domestically and internationally.  Most recently, she was a key member of the clinical team at AbbVie to expand the indications for Venclexta™, which the FDA recently approved for the treatment of chronic lymphocytic leukemia."

Dr. Brown has over 21 years of clinical research and development experience in designing and conducting phase 1 through phase 3 international clinical trials.  Most recently, Dr. Brown was Senior Medical Director at AbbVie, Inc. where she worked on the clinical development of Venclexta™ (venetoclax) in hematologic malignancies.  Previously, she served as a Senior Technical Analyst for RRD International, LLC and was Chief Medical Officer at Telik, Inc.  Earlier in her career, Dr. Brown consulted for a number of oncology start-up companies and participated in their scientific and clinical advisory boards.  Dr. Brown began her career at Harvard Medical School, where she served on the faculty of the Department of Medicine, Division of Hematology and Oncology at Brigham and Women's Hospital, New England Deaconess Hospital and the Dana Farber Cancer Institute.  She holds a M.D. degree from the University of Rochester School of Medicine and a M.B.A. degree from St. Mary's College of California Graduate School of Economics and Business Administration.

About ARMO BioSciences
Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company's lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. ARMO plans to initiate the first of several registration-enabling phase 2-3 studies for AM0010 in solid tumors. The company also has a robust pipeline of therapeutic cytokines and an anti-PD-1 checkpoint inhibitor.

For more information, please visit www.armobio.com

SOURCE ARMO BioSciences, Inc.

Related Links

http://www.armobio.com